Danaher Corporation $DHR Shares Purchased by First Manhattan CO. LLC.

Key Points

• First Manhattan CO. LLC. increased its stake in Danaher Corporation by 1.5% during the first quarter, owning approximately 1,933,460 shares valued at nearly $397 million.
• Multiple large investors, including Braidwell LP and Maverick Capital Ltd., have recently made significant purchases of Danaher shares, indicating strong institutional interest.
• Danaher reported $1.80 earnings per share for the last quarter, surpassing analyst expectations and showcasing a revenue increase of 3.4% year-over-year.

First Manhattan CO. LLC. lifted its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 1.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,933,460 shares of the conglomerate's stock after acquiring an additional 29,354 shares during the period. Danaher accounts for approximately 1.2% of First Manhattan CO. LLC.'s investment portfolio, making the stock its 17th biggest holding. First Manhattan CO. LLC. owned approximately 0.27% of Danaher worth $396,927,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Bank Pictet & Cie Europe AG boosted its stake in Danaher by 22.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after purchasing an additional 35,730 shares during the period. Gallagher Fiduciary Advisors LLC lifted its position in Danaher by 9.7% during the 4th quarter. Gallagher Fiduciary Advisors LLC now owns 1,065 shares of the conglomerate's stock worth $244,000 after acquiring an additional 94 shares during the period. Accredited Wealth Management LLC purchased a new position in shares of Danaher in the 4th quarter valued at approximately $40,000. Aptus Capital Advisors LLC increased its holdings in shares of Danaher by 8.6% in the fourth quarter. Aptus Capital Advisors LLC now owns 7,078 shares of the conglomerate's stock valued at $1,626,000 after purchasing an additional 562 shares during the period. Finally, Ancora Advisors LLC raised its stake in shares of Danaher by 2.2% during the fourth quarter. Ancora Advisors LLC now owns 7,020 shares of the conglomerate's stock worth $1,611,000 after purchasing an additional 149 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company's stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 11.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on DHR shares. UBS Group cut their price target on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft decreased their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price target on the stock in a research note on Friday, July 11th. Wells Fargo & Company decreased their price target on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 23rd. Finally, Guggenheim reiterated a "buy" rating and set a $250.00 target price on shares of Danaher in a research report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $246.35.

Danaher Price Performance

Shares of NYSE DHR traded down $0.47 during trading on Thursday, reaching $198.97. The company had a trading volume of 3,627,515 shares, compared to its average volume of 4,153,999. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The stock has a market capitalization of $142.47 billion, a PE ratio of 42.33, a price-to-earnings-growth ratio of 2.87 and a beta of 0.75. The stock has a 50-day moving average price of $201.94 and a two-hundred day moving average price of $199.49. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the previous year, the firm posted $1.72 earnings per share. The business's revenue for the quarter was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.